Governing AI-Assisted Sepsis Recognition in Viet Nam: Clinical Assessment, Time-Critical Response and Source-Control Accountability

Governing AI-Assisted Sepsis Recognition in Viet Nam: Clinical Assessment, Time-Critical Response and Source-Control Accountability

A patient recovering from abdominal surgery develops a fever and an increasing respiratory rate. During the evening shift, blood pressure begins to fall, and the patient becomes less responsive than earlier in the day.

An artificial intelligence (AI) system identifies a pattern associated with sepsis and generates an alert. The bedside nurse contacts the responsible physician, who immediately reassesses the patient.

The clinical picture raises concern for a serious infection, but several questions remain. Is the patient developing sepsis or septic shock? Could the deterioration have another cause, such as postoperative bleeding or pulmonary embolism? Is there an intra-abdominal infection that requires drainage or surgery? Which treatments should begin immediately, and what further investigation is needed?

The AI alert may have helped bring the patient to attention. It has not established the diagnosis, identified the source of infection or ensured that appropriate treatment will occur.

Even when antimicrobial therapy begins promptly, the patient's condition may continue to deteriorate if an infected collection or another source requiring intervention remains untreated.

This illustrates the difference between recognizing a possible clinical emergency and managing it effectively. For healthcare organizations in Viet Nam, AI-assisted sepsis recognition should operate within a clinical response process that connects timely assessment, appropriate treatment, coordination between services and clear accountability for source control.

The question is not simply whether AI can identify patients who may develop sepsis. It is whether hospitals can turn a potentially useful warning into appropriate care without delaying urgent treatment, increasing unnecessary interventions or overlooking other serious conditions.

Sepsis Is a Clinical Emergency, Not an Algorithmic Diagnosis

Sepsis is a life-threatening condition involving organ dysfunction caused by a dysregulated host response to infection.

The Sepsis-3 international consensus definitions, published in 2016, distinguish sepsis from uncomplicated infection by emphasizing organ dysfunction. Septic shock represents a more severe subset characterized by profound circulatory and metabolic abnormalities associated with increased mortality.

Under Sepsis-3, septic shock can be clinically identified in patients with sepsis who require vasopressors to maintain a mean arterial pressure of at least 65 mmHg and have a serum lactate concentration above 2 mmol/L despite adequate fluid resuscitation.

These criteria help standardize clinical definitions and research. However, recognition and treatment of potentially life-threatening illness must not be delayed while every element of a formal classification is being established.

In practice, sepsis can be difficult to recognize because its early manifestations overlap with several other clinical conditions.

Fever, tachypnea, tachycardia, hypotension, altered mental status and laboratory abnormalities may raise concern, but none of these findings is specific to sepsis.

A postoperative patient may develop fever and tachycardia because of infection. Similar findings can also occur with hemorrhage, pulmonary embolism, noninfectious inflammation or other complications. Some patients with sepsis do not develop fever, and older adults, immunocompromised patients or those with substantial underlying illness may present with subtle or atypical findings.

Organ dysfunction may also have several explanations. A rise in serum creatinine may reflect sepsis-associated acute kidney injury, but dehydration, medication effects and pre-existing kidney disease can contribute. Altered mental status may result from infection, metabolic abnormalities, neurological disease or medicines.

These possibilities require professional clinical assessment.

The Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 reinforces that sepsis is a clinical diagnosis and cannot be confirmed or excluded using a single biomarker or diagnostic test.

The same principle applies to artificial intelligence.

An AI model may identify patterns associated with sepsis, but a positive prediction is not equivalent to a confirmed diagnosis. A negative prediction cannot exclude sepsis when clinical findings remain concerning.

Healthcare organizations should therefore distinguish an AI-generated risk signal, a positive screening result, clinical suspicion of sepsis and an established diagnosis.

These states may overlap during emergency care, but they have different implications for treatment urgency, clinical decisions and performance measurement.

What the 2026 Surviving Sepsis Campaign Guidelines Mean for Hospitals

The Surviving Sepsis Campaign (SSC) published updated international guidelines for the management of adult sepsis and septic shock on March 23, 2026, updating the previous 2021 recommendations.

The update includes 129 statements, with 46 addressing topics not previously covered.

An important feature is the more explicit distinction between different levels of clinical suspicion and urgency, particularly when determining how quickly antimicrobial treatment should begin.

This matters because hospitals should not apply identical treatment decisions to every patient who triggers a sepsis screen.

The guideline also places considerable emphasis on implementation at the healthcare system level.

For hospitals and health systems, SSC 2026 recommends establishing sepsis performance improvement programs that include screening of acutely ill patients at increased risk, standard operating procedures for treatment and quality-improvement strategies.

It additionally suggests using multidisciplinary code sepsis or sepsis huddle approaches where appropriate.

These recommendations are relevant to AI governance because an electronic warning can draw attention to a patient, but the subsequent clinical response still requires an organized process for assessment, decision-making, intervention and reassessment.

For screening acutely ill patients in hospitals, SSC 2026 recommends using NEWS, NEWS2, MEWS or SIRS rather than relying on qSOFA as the sole screening tool.

These are clinical screening approaches rather than AI systems. Their purpose is to help identify patients who warrant further assessment, not to independently establish a sepsis diagnosis.

AI-based prediction may provide additional information, but its clinical usefulness needs to be evaluated against existing screening and response processes.

The guideline also addresses antimicrobial stewardship, individualized hemodynamic resuscitation, evaluation for source control and care following the acute episode.

Together, these recommendations reinforce why sepsis recognition should be governed as part of a clinical pathway rather than as a standalone prediction task.

SSC 2026 primarily addresses adults. Pediatric sepsis, maternal sepsis and other specialized populations may require separate or additional clinical guidance. An AI application validated among general adult inpatients should not automatically be extended to these populations.

Understanding What an AI Sepsis System Actually Does

Healthcare organizations should establish the intended function of a sepsis system before evaluating its clinical performance.

A conventional electronic screening application may calculate NEWS2, MEWS or another clinical score using recorded observations. A rule-based system may generate an alert when predefined combinations of vital signs or laboratory abnormalities occur.

These systems can be clinically useful, but automated scoring does not necessarily involve artificial intelligence.

Machine-learning models perform different functions. They may analyze patterns across electronic health records, including physiological measurements, laboratory results, medication information, diagnoses and previous clinical observations.

Some models estimate the probability that a patient will meet a defined sepsis outcome during a future period. Others attempt to recognize possible sepsis that is already developing.

Large language models may also be used to extract information from clinical notes, summarize relevant findings or assess the completeness of documented care.

These functions should not be treated as interchangeable.

A model designed to predict future sepsis is not necessarily validated to diagnose patients who are already deteriorating. A system that identifies possible infection-related organ dysfunction cannot automatically determine which antimicrobial treatment is indicated. An application that reviews sepsis documentation for quality improvement does not necessarily identify sepsis earlier or improve emergency decision-making.

Each function requires evidence appropriate to its intended clinical purpose.

Hospitals should also understand how the target outcome was defined during model development and validation.

Some studies use Sepsis-3 criteria, while others rely on combinations of antimicrobial administration, microbiology investigations, laboratory results or administrative codes.

These definitions may identify overlapping but different patient populations.

A model performing well against a retrospective electronic definition may not identify every patient who requires urgent sepsis care. Conversely, an AI alert may be clinically reasonable even when the patient does not subsequently meet the study's formal outcome definition.

The interpretation of predictive accuracy therefore depends partly on what was predicted, when the prediction was generated and how the clinical outcome was defined.

Data Quality and Clinical Context Can Change an AI Prediction

AI-assisted sepsis recognition depends on accurate and timely clinical information.

Vital signs may be recorded at different intervals across departments. Laboratory results may become available after substantial delays, and medication orders may not establish which treatments have already been administered.

Important observations may appear in narrative clinical notes before they are entered into structured electronic fields. A patient may also deteriorate between scheduled observations, particularly when monitoring is intermittent.

These differences affect the information available to an AI model and may change its predictions.

The timing of data is especially important when evaluating systems described as providing early warnings.

A model may use a blood pressure measurement documented after clinical deterioration was already recognized. If retrospective evaluation does not preserve when information actually became available, the model may appear capable of predicting deterioration earlier than would have been possible in clinical practice.

This form of information leakage can produce misleading performance estimates.

A system should not receive credit for predicting an event before clinical recognition if it relied on information that became available only afterward.

Patient populations also differ substantially between clinical settings.

A model developed primarily among general medical inpatients may perform differently in postoperative patients, oncology patients, immunocompromised individuals or critically ill patients.

Sepsis-like physiological abnormalities may be common in certain departments even when infection is absent. Without appropriate local validation, these differences can produce excessive false-positive alerts or clinically important missed cases.

Missing information creates another problem.

An AI system should not automatically interpret the absence of a documented laboratory abnormality or clinical symptom as evidence that no abnormality exists.

Where important information is unavailable, the limitations should be recognized and reflected in the interpretation of the output.

The responsible clinician must remain able to review the patient's condition and determine whether the findings require immediate treatment, further investigation or continued monitoring.

From an AI Alert to Timely Clinical Assessment

A sepsis alert becomes clinically useful only when it reaches someone who can respond appropriately.

Hospitals need a reliable process for reviewing alerts, assigning responsibility and determining when escalation is necessary.

For example, an alert generated on a medical ward may reach the bedside nurse, who reassesses the patient's condition and contacts the responsible physician when appropriate.

If the patient has severe hypotension, respiratory compromise, altered mental status or other concerning findings, the response should follow the hospital's established emergency assessment and escalation procedures.

The clinical team should not wait for the AI system to generate a higher risk score before responding to obvious deterioration.

At the same time, not every positive sepsis prediction requires activation of the same emergency response.

A clinically stable patient with possible infection may require prompt evaluation rather than immediate critical care intervention. This distinction should be reflected in the workflow.

The SSC 2026 recommendation concerning sepsis huddles provides one approach to coordinating clinical decisions.

A multidisciplinary huddle may allow physicians and nurses to review the likelihood of infection, evidence of organ dysfunction, current physiological status, immediate treatment needs and possible infectious sources.

The purpose is to accelerate appropriate decisions, particularly when information is incomplete or several professionals need to coordinate care.

However, a huddle should not become an administrative prerequisite that delays treatment when emergency intervention is already indicated.

Hospitals also need arrangements for situations in which the responsible clinician is unavailable, several alerts occur simultaneously or the patient's condition deteriorates during the initial assessment.

An accurate alert may have little practical value if the response process is unreliable.

Acknowledging an alert electronically is not evidence that the patient has been appropriately assessed or treated. The clinical record should make it possible to establish whether the concern was reviewed, what decisions were made and whether necessary actions occurred.

Antimicrobial Timing Must Reflect Clinical Probability and Severity

The timing of antimicrobial treatment is one of the most important aspects of sepsis care and one of the easiest to misinterpret when AI is introduced.

SSC 2026 distinguishes between several clinical situations.

For adults with possible, probable or definite septic shock, the guideline recommends administering antimicrobial therapy immediately, ideally within one hour of recognition.

For adults with probable or definite sepsis without shock, it also recommends immediate antimicrobial treatment, ideally within one hour of recognition.

For adults with possible sepsis without shock, the approach is different.

The guideline suggests a time-limited period of rapid investigation. If concern for infection persists, antimicrobial treatment should be administered within three hours from the time sepsis was first suspected.

The period of investigation should support rapid clinical decision-making rather than become a reason for unnecessary delay. If clinical assessment establishes that bacterial infection is the most likely cause, treatment should begin without waiting unnecessarily for the full investigation window to expire.

For patients without shock and with a low likelihood of infection, the guideline suggests deferring antimicrobial therapy while continuing close clinical monitoring.

These distinctions have important implications for AI-assisted recognition.

A positive AI prediction should not automatically become an instruction to administer broad-spectrum antibiotics within one hour.

Doing so could increase unnecessary antimicrobial exposure, adverse drug reactions, disruption of normal microbiota and selective pressure for antimicrobial resistance.

Conversely, a patient with suspected septic shock should not experience treatment delays because an AI model assigns a low sepsis probability.

Clinical suspicion and urgency must remain central to treatment decisions.

SSC 2026 recommends obtaining blood cultures as soon as possible and ideally before antimicrobial administration when sepsis or septic shock is suspected.

However, culture collection should be organized without inappropriately delaying urgent treatment.

Blood lactate measurement can assist clinical assessment and monitoring, but elevated lactate is not specific to sepsis. A normal concentration also does not independently exclude the condition.

Procalcitonin has limitations as well.

SSC 2026 suggests using clinical evaluation alone rather than adding procalcitonin when deciding whether to initiate antimicrobial therapy in adults with possible or probable sepsis or septic shock.

This recommendation concerning treatment initiation should be distinguished from the separate, more limited circumstances in which procalcitonin may help inform decisions about discontinuing antimicrobial therapy. For example, the guideline suggests combining procalcitonin with clinical evaluation when source control is adequate but the optimal antimicrobial duration remains uncertain.

These distinctions reinforce that isolated biomarkers, laboratory thresholds and AI scores should not independently determine antimicrobial treatment.

AI may help organize available information, but antimicrobial decisions must reflect the patient's condition, the likelihood of infection and relevant clinical evidence.

Antimicrobial Stewardship in the Vietnamese Context

Appropriate antimicrobial treatment matters beyond the individual patient because unnecessary use contributes to antimicrobial resistance.

Viet Nam's National Strategy on Antimicrobial Resistance Prevention and Control for 2023–2030, with a vision to 2045, was approved through Prime Ministerial Decision No. 1121/QĐ-TTg on September 25, 2023.

The strategy emphasizes responsible antimicrobial use, surveillance of antimicrobial resistance, infection prevention and coordinated action across relevant sectors.

This national policy context is important for AI-assisted sepsis recognition.

A system that produces large numbers of false-positive alerts could encourage unnecessary antimicrobial treatment if the hospital does not have an appropriate clinical review process.

However, antimicrobial stewardship must not become a justification for delaying necessary treatment in patients with probable or definite sepsis or septic shock.

The clinical challenge is to provide effective treatment promptly when indicated while avoiding unnecessary exposure in patients whose findings are more likely to reflect noninfectious illness.

The choice of empirical antimicrobial treatment also depends on the suspected source, likely pathogens, previous microbiological information, patient-specific risk factors and local resistance patterns.

AI prediction of sepsis does not independently determine these considerations.

Once microbiological results and additional clinical information become available, treatment should be reassessed.

SSC 2026 supports antimicrobial de-escalation where appropriate, including narrowing treatment or discontinuing unnecessary coverage according to microbiological findings and clinical circumstances.

A well-governed sepsis process should therefore support both timely initiation when indicated and appropriate reassessment afterward.

The objective is not to maximize antibiotic administration. It is to ensure that patients receive effective treatment when needed while unnecessary exposure is minimized.

Time-Critical Sepsis Care Extends Beyond Antibiotics

Antimicrobial treatment is important, but it is only one component of managing sepsis and septic shock.

Patients with sepsis-induced hypoperfusion or septic shock may require hemodynamic resuscitation, organ support and frequent reassessment.

Clinical care must address circulation, oxygenation, renal function, neurological status and other relevant aspects of organ dysfunction.

SSC 2026 suggests administering at least 30 mL/kg of intravenous crystalloid during the first three hours for adults with sepsis-induced hypoperfusion or septic shock.

This is a conditional recommendation supported by low-certainty evidence.

The guideline emphasizes consideration of individual patient characteristics when selecting the initial fluid volume, together with frequent reassessment to avoid both inadequate resuscitation and fluid overload.

These qualifications matter in clinical practice.

A patient with substantial hypoperfusion may require prompt fluid administration. Another patient with heart failure, pulmonary edema or significant fluid accumulation requires careful evaluation of the benefits and risks of further fluids.

The recommended initial volume should not be interpreted as an instruction to administer identical treatment to every patient with a positive sepsis screen.

A rigid electronic rule that automatically triggers fluid administration without clinical assessment could be unsafe.

Similarly, AI predictions should not independently initiate vasopressors, modify respiratory support or generate other treatment orders solely because a probability threshold has been exceeded.

Such decisions require professional assessment, appropriate monitoring and reassessment of the patient's response.

A useful sepsis workflow should support recognition of urgent physiological problems, coordination of necessary resources and timely review of whether treatment is achieving its intended effects.

Source Control Is a Distinct Clinical Responsibility

One reason sepsis may continue to progress despite timely antimicrobial therapy is that the underlying infectious source has not been adequately controlled.

Source control refers to interventions intended to eliminate, drain, remove or otherwise control an infectious focus when such action is clinically indicated.

Examples include drainage of an infected collection, treatment of an infected and obstructed urinary system, surgical management of infected tissue or removal of an infected device when appropriate.

These interventions involve different specialists and require different clinical decisions.

Not every patient with sepsis requires surgery, drainage or another invasive procedure. For many infections, antimicrobial treatment and supportive care may be sufficient.

The first responsibility is to identify whether an anatomical source requiring intervention is present or reasonably suspected.

SSC 2026 recommends rapid evaluation for specific anatomical diagnoses or sources of infection that require emergency source control.

For adults with sepsis or septic shock and a specific source requiring intervention, the guideline suggests early rather than delayed source control, ideally within six hours of the diagnosis of sepsis or septic shock requiring source control.

This is a conditional recommendation based on very low-certainty evidence.

The six-hour timeframe should not be converted into an inflexible requirement for every patient with sepsis.

The appropriate timing and method depend on the anatomical problem, clinical stability, feasibility of intervention and risks associated with delay.

Nevertheless, the recommendation highlights an important organizational responsibility.

Once source control is clinically indicated, someone must ensure that the relevant assessment, specialist consultation and intervention are coordinated.

Antibiotic administration alone does not establish that this responsibility has been fulfilled.

What Source-Control Accountability Means in Practice

Consider a patient with suspected intra-abdominal sepsis whose CT examination demonstrates a collection that may require drainage.

The clinical team must determine whether the imaging findings and the patient's condition support intervention.

If source control is indicated, the responsible clinician needs to coordinate with the appropriate surgical or interventional team and ensure that the plan is communicated.

This may involve further imaging review, resuscitation, anesthesia assessment, procedural preparation and access to the necessary expertise.

A consultation request does not establish that source control has been achieved. Similarly, a recommendation for drainage is not evidence that the procedure was performed.

Hospitals should distinguish between identifying a potential infectious source, determining whether an intervention is required, arranging the appropriate service and confirming that the clinical plan has been implemented.

Where an intervention cannot be performed promptly, the responsible team should document the reason, establish an appropriate interim or alternative plan and continue reassessment.

Sometimes specialist review determines that an invasive procedure is not necessary. This may be an appropriate clinical conclusion rather than a failure of source control.

The governance objective is to ensure that the decision is explicit, clinically justified and acted upon.

AI-assisted systems may help identify unresolved source-control tasks or recognize documentation suggesting that an agreed intervention has not occurred.

However, software that tracks whether a procedure order exists cannot independently determine whether the intervention was clinically necessary or whether adequate source control was achieved.

Those judgments require professional clinical evaluation.

Quality measures should therefore focus on patients with established indications for source control rather than treating every patient with sepsis as eligible for invasive intervention.

This avoids encouraging unnecessary procedures merely to meet performance targets.

What the 2026 Evidence Shows About Sepsis Prediction Models

Research published in 2026 illustrates both the progress and the limitations of AI-assisted sepsis prediction.

A multicenter study by Wong and colleagues, published in JAMA Network Open on February 27, 2026, prospectively validated Epic Sepsis Model version 2 across four major healthcare systems in the United States.

The study included 227,091 inpatient encounters, of which 7,401 met the study's Sepsis-3 criteria.

At the encounter level, the model achieved an area under the receiver operating characteristic curve (AUROC) ranging from 0.82 to 0.92 across participating health systems.

These results indicate useful discrimination in the populations studied.

However, performance varied according to the evaluation method and prediction horizon.

For predictions within a 12-hour horizon, AUROC ranged from 0.75 to 0.85.

At institution-specific score thresholds selected to achieve approximately 60% sensitivity, positive predictive values ranged from 0.13 to 0.26.

This means that many encounters generating positive predictions at those thresholds did not meet the study's defined sepsis outcome.

The researchers also identified substantial variation across healthcare systems and a considerable alert burden.

The updated model demonstrated better discrimination than its predecessor, but the study did not establish that implementing its alerts reduced sepsis mortality or improved other clinical outcomes.

These distinctions are important when evaluating model performance.

An AUROC near 0.90 may appear impressive, but it does not tell hospital leaders how many alerts staff will receive during a typical shift, how many require meaningful action or how frequently important cases will be missed.

Positive predictive value depends on the prevalence of the outcome, the selected alert threshold and the population being assessed.

A hospital with a different case mix or sepsis incidence may therefore experience substantially different operational performance.

The study supports local validation, careful threshold selection, alert management and integration with reliable clinical response procedures.

It does not justify assuming that a model evaluated in American hospitals will perform equally well in Vietnamese healthcare settings.

AI Can Also Support Sepsis Quality Monitoring

AI may contribute to sepsis care through functions other than predicting clinical deterioration.

A cluster-randomized trial by Boussina and colleagues, published in JAMA Network Open on June 25, 2026, evaluated an AI-enabled approach to reviewing medical records and providing targeted quality feedback.

The study involved 66 attending physicians and 301 eligible patient encounters across two emergency departments within one academic healthcare system in the United States.

A large language model was used to assess clinical records against the Centers for Medicare & Medicaid Services Severe Sepsis and Septic Shock Management Bundle measure, known as SEP-1.

Physicians assigned to the intervention received targeted feedback based on AI-assisted review of relevant cases.

The intervention supported a quality-improvement feedback process rather than providing autonomous treatment instructions during emergency care.

Overall SEP-1 compliance was 82.9% in the intervention group compared with 70.1% in the control group, based on encounters with complete data for the primary compliance analysis.

The statistical analysis identified a significant improvement in the primary quality measure associated with the intervention.

However, the study did not demonstrate statistically significant differences in intensive care admission or 30-day mortality.

The most pronounced difference among individual process components concerned the crystalloid fluid administration component of SEP-1.

The language model's assessment also demonstrated substantial, but not perfect, agreement with expert review.

These findings suggest that AI may help evaluate complex clinical documentation and provide timely feedback to healthcare professionals.

Nevertheless, the intervention was not an autonomous sepsis diagnostic or treatment system. It did not establish that an LLM could independently determine the correct clinical treatment for every patient.

SEP-1 is also a United States healthcare quality measure. It should not be presented as a mandatory Vietnamese clinical standard or as interchangeable with every recommendation in SSC 2026.

Compliance with a quality measure does not necessarily establish that care was optimal for each individual patient.

The study is best understood as evidence that AI-supported documentation review and targeted feedback may improve selected quality processes.

Whether these improvements translate into better clinical outcomes requires further investigation.

Applying International Guidance in Vietnamese Healthcare

Sepsis care in Viet Nam must reflect national professional guidance, current clinical evidence and the resources available within individual healthcare organizations.

Ministry of Health Decision No. 1493/QĐ-BYT, issued on April 22, 2015, introduced the professional guidance Guidelines for Diagnosis and Management in Intensive Care (Hướng dẫn chẩn đoán và xử trí hồi sức tích cực).

The document includes material relevant to septic shock and other critical care conditions.

It provides an important national professional reference, but it was developed before the Sepsis-3 definitions and the SSC 2026 update.

Some terminology, diagnostic approaches and treatment recommendations may therefore differ from more recent international evidence.

Hospitals should review locally approved sepsis protocols against applicable Vietnamese professional requirements and current clinical guidance rather than assuming that an older national document or a newer international publication automatically replaces the other.

The clinical setting also matters.

Large tertiary hospitals may have emergency response teams, intensive care services, microbiology laboratories, advanced imaging, interventional radiology and specialized surgical support.

Smaller facilities may have more limited resources and depend on referral arrangements for advanced source-control procedures or critical care.

These differences influence how an AI-assisted system can be used safely.

An alert may identify a patient who requires urgent intervention, but it cannot make an unavailable specialist, operating room or transfer service immediately accessible.

Hospitals need practical pathways for obtaining the required care, including escalation and referral when necessary.

Before introducing AI, healthcare organizations should understand where delays occur within their existing sepsis response process.

One hospital may recognize suspected sepsis promptly but experience delays obtaining appropriate antimicrobials. Another may initiate emergency treatment reliably but have inconsistent procedures for evaluating and arranging source control.

A third may already use an electronic warning system that generates excessive alerts without providing clinically useful information.

These situations require different improvements.

AI should be selected to address a defined clinical or operational problem rather than introduced simply because predictive technology is available.

Validating AI Before Routine Clinical Deployment

Hospitals considering AI-assisted sepsis recognition should begin by defining the intended use.

The system may be designed to predict sepsis before clinical recognition, identify possible infection-related organ dysfunction or support retrospective or near-real-time quality review.

These functions should be evaluated separately.

The target population, outcome definition, prediction horizon, expected clinical response and setting need to be established before validation begins.

The organization should determine whether the necessary information is available and reliable in its own clinical systems.

Vital signs, laboratory data, antimicrobial records, microbiology results and clinical notes may be documented differently across departments.

A model trained using integrated electronic health records may perform poorly when introduced into a facility with incomplete information or delayed data entry.

Local validation should include representative patients and clinical circumstances.

For adult hospital use, these may include emergency department patients, general medical inpatients and postoperative patients, provided those populations fall within the application's intended scope.

Performance should be examined across departments, age groups and clinically relevant patient categories.

Patients with noninfectious deterioration deserve particular attention because they may generate false-positive sepsis alerts.

Cases not flagged by the system must also be evaluated. Otherwise, clinically important false-negative predictions may remain undetected.

Performance assessment should include discrimination, calibration, sensitivity, positive predictive value, alert volume and clinically meaningful lead time.

A model that identifies sepsis only shortly before clinicians would ordinarily recognize it may provide limited additional benefit.

Conversely, an earlier prediction may not improve care if staff lack sufficient information or resources to respond appropriately.

The evaluation should also consider whether the system's performance changes when laboratory processes, documentation practices or patient populations change.

Technical validation alone should not be treated as evidence that the application is ready for unrestricted clinical deployment.

The complete workflow must also be assessed, including who receives alerts, whether staff have sufficient capacity to review them, which actions are expected and how urgent concerns are escalated.

Measuring Clinical Response Rather Than Alert Activity

The number of AI-generated sepsis alerts is not an adequate measure of patient safety.

Hospitals need to determine whether the system improves recognition, professional assessment and clinically appropriate intervention.

The first stage concerns the accuracy and timeliness of identification.

The organization should examine whether clinically important cases are recognized, how often unnecessary alerts occur and whether predictions provide useful lead time.

The next stage concerns clinical response.

Relevant measures may include time from recognition to bedside assessment, the proportion of alerts receiving meaningful professional review and the frequency of delayed or missed escalation.

The starting point for time-based measures must be carefully defined.

The time an AI alert was generated is not necessarily the time sepsis was clinically suspected or recognized.

Using an inappropriate starting point can create misleading estimates of treatment timeliness.

Antimicrobial measures should reflect clinical probability and severity.

For patients with septic shock or probable or definite sepsis without shock, timely treatment is essential.

For possible sepsis without shock, appropriate rapid investigation may precede antimicrobial administration.

It would therefore be incorrect to classify every AI-positive patient who did not receive antibiotics within one hour as a treatment failure.

Hospitals should also examine whether antimicrobial therapy was clinically appropriate and whether treatment was reassessed as new information became available.

Source-control measures require equally careful definitions.

The relevant denominator should include patients with an established clinical indication for intervention.

Evaluation may examine whether the source was assessed, whether the appropriate specialist was involved, whether a plan was agreed and whether the indicated intervention occurred within a clinically justified timeframe.

Clinical outcomes may include progression to septic shock, intensive care admission, organ support requirements, length of stay and mortality.

These outcomes require careful interpretation because illness severity, patient characteristics and timing of presentation influence results.

Changes in outcomes should not automatically be attributed to AI when other aspects of clinical care have changed.

Balancing measures are equally important.

These may include unnecessary antimicrobial treatment, inappropriate intravenous fluid administration, avoidable investigations, excessive alerts, staff workload and delays in recognizing noninfectious causes of deterioration.

A hospital should not regard increased antibiotic administration or a larger number of sepsis alerts as evidence of improved care without considering clinical appropriateness.

The objective is to improve the reliability and safety of the complete clinical response.

Learning From Missed Cases and False-Positive Alerts

A well-governed sepsis program should investigate both missed clinical deterioration and unnecessary alerts.

Consider a patient who develops septic shock without an earlier AI warning.

The review should examine whether relevant vital signs were recorded, whether laboratory results were delayed and whether the model had sufficient information to recognize the developing problem.

However, the absence of an alert should not automatically be considered the cause of the patient's deterioration.

The organization must also assess whether clinicians recognized other warning signs and whether established monitoring and escalation procedures functioned appropriately.

In another situation, AI may generate repeated sepsis alerts for a patient with a noninfectious inflammatory condition.

If staff respond by repeatedly ordering investigations or administering unnecessary antibiotics, the system may introduce avoidable harm.

The review should determine whether the alert threshold is unsuitable for the patient population, whether its inputs are misleading or whether the clinical workflow lacks an effective way to manage repeated nonactionable warnings.

Some alerts may be clinically reasonable even when sepsis is ultimately excluded.

A patient may present with findings that justify urgent assessment before the diagnosis becomes clear.

A false-positive prediction according to a retrospective research definition does not necessarily mean that the original clinical concern was inappropriate.

Hospitals should therefore distinguish between model error, reasonable clinical uncertainty and failures in the response process.

These reviews should lead to practical improvements, such as adjusting alert thresholds, improving data quality, clarifying escalation responsibilities or strengthening clinical training.

Where a system repeatedly misses serious cases, produces unsafe recommendations or generates an unmanageable alert burden, the organization should have authority to restrict, suspend or discontinue its use.

Essential sepsis assessment and treatment must remain available when AI is unreliable or unavailable.

Continuity of Care After Sepsis

For patients who survive sepsis, recovery may extend beyond the initial hospitalization.

Some patients experience persistent weakness, cognitive difficulties, emotional symptoms or new care needs.

SSC 2026 emphasizes communication during care transitions, medication reconciliation, patient and caregiver education and appropriate follow-up for new or continuing impairments.

These recommendations are relevant to overall healthcare quality, although they are not the principal focus of AI-assisted early sepsis recognition.

A patient whose infection has been controlled may still require rehabilitation, medication review or additional medical assessment.

Discharge planning should communicate relevant diagnoses, treatments, complications and follow-up needs to patients, caregivers and subsequent healthcare professionals as appropriate.

AI may eventually support identification of unresolved recovery needs, but this represents a separate application requiring its own evaluation.

For healthcare organizations implementing sepsis prediction technology, the immediate responsibility is to ensure that acute care does not become disconnected from the patient's subsequent recovery needs.

Legal and Professional Responsibilities in Viet Nam

AI-assisted sepsis recognition must operate within Viet Nam's applicable healthcare, artificial intelligence, medical device and personal data protection frameworks.

These legal areas address different responsibilities. Compliance with one does not automatically establish compliance with another or demonstrate that a particular clinical application is safe.

Clinical Practice and Hospital Quality Responsibilities

The Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, as subsequently amended, provides an important legal foundation for professional healthcare practice, patient rights, medical records and healthcare organizational responsibilities.

Ministry of Health Decision No. 1493/QĐ-BYT remains a relevant national professional reference for critical care, subject to its applicable provisions and subsequent professional developments.

Circular No. 31/2021/TT-BYT provides requirements concerning nursing activities in hospitals, including assessment, monitoring, care, coordination and documentation.

Circular No. 43/2018/TT-BYT addresses prevention of medical incidents, reporting, analysis and learning within healthcare facilities.

Circular No. 19/2013/TT-BYT provides an organizational framework for hospital quality management, subject to applicable subsequent legal and regulatory changes.

These instruments establish relevant professional and organizational responsibilities for healthcare quality and patient safety.

However, they should not be interpreted as establishing a universal requirement to use AI for sepsis prediction or mandating any particular commercial technology.

Hospitals should establish who is authorized to assess suspected sepsis, make treatment decisions, coordinate specialist services and oversee unresolved clinical concerns.

AI does not independently replace these professional responsibilities.

Artificial Intelligence Regulation

Viet Nam's Law on Artificial Intelligence No. 134/2025/QH15 took effect on March 1, 2026.

Decree No. 142/2026/NĐ-CP, effective May 1, 2026, provides implementing provisions concerning AI activities and relevant responsibilities.

Decision No. 33/2026/QĐ-TTg, effective August 15, 2026, establishes the List of High-Risk Artificial Intelligence Systems.

The regulatory classification of a sepsis AI product cannot be determined solely from the fact that it is used in healthcare.

The assessment needs to consider its intended purpose, actual functions, degree of automation, deployment arrangements and applicable legal criteria.

A system that provides risk predictions for professional review may raise different concerns from software intended to make autonomous clinical decisions.

The absence of a product's specific name from a high-risk list should not be treated as proof that the application is automatically low-risk or exempt from applicable requirements.

Clinical risk also requires separate evaluation.

A system that misses sepsis, generates misleading treatment recommendations or delays urgent clinical assessment may pose significant patient-safety risks regardless of its formal statutory classification.

Medical Device Requirements

Some healthcare AI applications may fall within Viet Nam's medical device regulatory framework, depending on their intended medical purpose and functions.

Decree No. 98/2021/NĐ-CP on medical device management, as amended, provides part of the applicable framework.

Ministry of Health Circular No. 24/2026/TT-BYT, effective July 1, 2026, addresses risk determination and management measures for products classified as medical devices and amends relevant implementing provisions.

A product designed to perform administrative reporting may have a different intended purpose from software promoted to support clinical prediction, diagnosis or treatment decisions.

The presence of machine learning does not automatically determine medical device status.

Conversely, describing an AI product as a workflow application does not necessarily exclude medical device requirements if its actual intended functions have a medical purpose.

Regulatory classification and applicable obligations should be assessed for the specific product and deployment.

Authorization or certification obtained in another jurisdiction may provide useful information, but it does not independently establish compliance with Vietnamese law.

Protecting Patient Information and Defining Vendor Accountability

AI-assisted sepsis systems may process identifiable diagnoses, laboratory results, physiological observations, microbiology findings, medication information and other clinical records.

Such information requires appropriate protection.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, provide relevant requirements concerning personal data processing and protection.

Healthcare organizations should establish the applicable lawful basis and purposes for processing, including relevant consent requirements or legally applicable exceptions.

Access should be restricted to authorized personnel, with appropriate information security, retention and accountability arrangements.

Where external technology providers participate, responsibilities for system maintenance, access to patient information, data processing, security incidents and operational support should be clearly defined.

Hospitals should also determine whether patient information may be used for AI model development, training or commercial improvement.

Clinical data collected for patient care should not automatically be reused for unrelated commercial purposes without assessing the applicable legal basis and required safeguards.

External hosting or cross-border processing arrangements may create additional legal obligations.

These matters should be addressed before identifiable patient information is transferred to an external AI service.

AI governance also requires operational accountability.

A technology provider may be responsible for software maintenance and particular technical functions, but this does not automatically make the provider responsible for the hospital's clinical response to an alert.

At the same time, providers and healthcare organizations may each have legal, contractual and operational responsibilities arising from their respective roles.

The healthcare organization should establish who monitors the system, reviews performance, manages failures and decides whether the technology remains appropriate for clinical use.

International clinical guidelines can inform local professional practice, but they do not automatically become binding Vietnamese legal requirements.

Similarly, organizational safeguards proposed in this article should be distinguished from mandatory legal obligations unless a specific applicable provision establishes such a requirement.

A Practical Starting Point for Vietnamese Hospitals

A hospital considering AI-assisted sepsis recognition should begin by reviewing its existing sepsis care pathway.

A focused assessment may examine patients treated for suspected sepsis or septic shock in the emergency department and selected inpatient wards.

The organization can determine when clinical deterioration was recognized, how quickly professional assessment occurred and whether treatment reflected the patient's condition and the likelihood of infection.

The review should also examine whether sources requiring intervention were identified and whether necessary source-control procedures were arranged.

This assessment may reveal weaknesses that do not require AI.

A hospital may already recognize sepsis promptly but have inconsistent arrangements for contacting specialist services. Another may initiate antimicrobial treatment effectively but experience delays in evaluating the infectious source.

A third may have an electronic warning system that generates substantial workload without offering useful clinical information.

The appropriate first response may involve clearer procedures, multidisciplinary training, better communication or improved access to essential services.

If AI appears likely to provide additional benefit, the organization should select a limited use case.

One possibility is evaluating whether a prediction model can identify adult inpatients at increased risk of sepsis before existing clinical processes recognize the concern.

Another is using AI to support clinical documentation review and quality measurement.

These functions should be evaluated separately.

An initial silent evaluation may allow the system to generate predictions without influencing treatment decisions.

This enables assessment of data reliability, missed cases, false alerts, calibration and model performance while established clinical care continues.

If local validation and operational readiness are satisfactory, a limited supervised clinical pilot may be considered.

During the pilot, the hospital should define who receives alerts, how they are reviewed, which clinical actions are expected and how urgent concerns are escalated.

Monitoring should include whether the system improves appropriate care, whether false alerts cause unnecessary treatment and whether staff can manage the workload.

Clinical leadership, nursing, emergency medicine, critical care, infectious disease specialists, clinical pharmacy, microbiology, surgery, interventional services, information technology and quality management may all contribute according to available resources.

Results should be reviewed through established clinical governance and patient-safety processes.

Expansion should depend on demonstrated reliability, acceptable clinical risk and evidence of practical benefit.

A model evaluated in adult emergency department or general medical patients should not automatically be introduced into pediatric, obstetric or other specialized populations without appropriate assessment.

The objective is to strengthen the hospital's sepsis response process, not make essential clinical care dependent on a prediction model.

From Sepsis Alerts to Safer Clinical Care

Sepsis provides an important example of what responsible AI governance means in clinical practice.

AI can help healthcare organizations recognize patterns of deterioration, identify patients who may require assessment and review complex clinical documentation.

Research published in 2026 demonstrates progress in these capabilities.

However, accurate prediction does not guarantee that an appropriate clinical response will occur. Improvements in quality measures also do not automatically establish better survival or other patient outcomes.

SSC 2026 reinforces the importance of timely clinical assessment, antimicrobial treatment that reflects infection probability and severity, individualized resuscitation and evaluation for source control.

For healthcare organizations in Viet Nam, AI should operate within that clinical framework, supported by clearly assigned responsibilities and reliable pathways for urgent action.

A patient with suspected septic shock requires immediate care even when no AI warning has been generated.

A patient with a positive AI prediction but a low likelihood of infection requires appropriate assessment rather than automatic antimicrobial treatment.

A patient whose infection requires drainage, surgery or another source-control intervention should not be considered adequately managed simply because antibiotics have been started.

The success of an AI-assisted sepsis program should not be defined by the number of alerts generated or the predictive accuracy reported in a published study.

It should be reflected in whether clinically important deterioration is recognized, patients receive appropriate treatment for their level of urgency, necessary source-control decisions are implemented and avoidable harm is minimized.

AI can help identify when sepsis may be developing. Safe care depends on what the healthcare organization does next.

Selected References and Regulatory Sources

International Clinical Guidelines

Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Intensive Care Medicine. 2026;52:863–936. DOI: 10.1007/s00134-026-08361-1.

Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Critical Care Medicine. 2026. DOI: 10.1097/CCM.0000000000007075.

Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.

World Health Organization. Sepsis. Fact Sheet. Updated May 3, 2024.

Clinical AI and Implementation Evidence

Wong A, Currey D, Schwinne M, et al. Multicenter Prospective Validation of an Updated Proprietary Sepsis Prediction Model. JAMA Network Open. 2026;9(2). DOI: 10.1001/jamanetworkopen.2026.0181.

Boussina A, Allison C, Quintero K, et al. Medical Record Abstraction for Quality Improvement in Sepsis Care Using Artificial Intelligence: A Cluster Randomized Trial. JAMA Network Open. 2026;9(6). DOI: 10.1001/jamanetworkopen.2026.11885.

Vietnamese Clinical and Healthcare Quality Guidance

Ministry of Health of Viet Nam. Decision No. 1493/QĐ-BYT, dated April 22, 2015, issuing the professional guidance Guidelines for Diagnosis and Management in Intensive Care (Hướng dẫn chẩn đoán và xử trí hồi sức tích cực).

Ministry of Health of Viet Nam. Circular No. 31/2021/TT-BYT on Nursing Activities in Hospitals.

Ministry of Health of Viet Nam. Circular No. 43/2018/TT-BYT on Prevention of Medical Incidents in Healthcare Facilities.

Ministry of Health of Viet Nam. Circular No. 19/2013/TT-BYT on Hospital Quality Management, subject to applicable subsequent legal and regulatory changes.

Prime Minister of Viet Nam. Decision No. 1121/QĐ-TTg, dated September 25, 2023, approving the National Strategy on Antimicrobial Resistance Prevention and Control for 2023–2030, with a vision to 2045.

Relevant Vietnamese Legal and Regulatory Framework

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, as subsequently amended.

National Assembly of Viet Nam. Law on Artificial Intelligence No. 134/2025/QH15, effective March 1, 2026.

Government of Viet Nam. Decree No. 142/2026/NĐ-CP, detailing certain provisions and measures for implementing the Law on Artificial Intelligence, effective May 1, 2026.

Prime Minister of Viet Nam. Decision No. 33/2026/QĐ-TTg, promulgating the List of High-Risk Artificial Intelligence Systems, effective August 15, 2026.

Government of Viet Nam. Decree No. 98/2021/NĐ-CP on Medical Device Management, as amended.

Ministry of Health of Viet Nam. Circular No. 24/2026/TT-BYT on Risk Determination and Management Measures for Medical Devices and Amendments to Related Implementing Provisions, effective July 1, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15, effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/NĐ-CP, detailing certain provisions and measures for implementing the Law on Personal Data Protection, effective January 1, 2026.

Editorial and Clinical Notice

This article is intended for professional education, responsible healthcare AI governance and healthcare quality-improvement discussion. The opening clinical scenario is illustrative and does not describe an identified patient or documented clinical incident.

The article summarizes selected international clinical guidance, published research, Vietnamese professional requirements and relevant legal and regulatory considerations. It also describes proposed organizational approaches for AI-assisted sepsis recognition, time-critical clinical response, antimicrobial stewardship, source-control coordination and performance monitoring.

These approaches do not constitute a mandatory Vietnamese AI implementation standard, an independently validated sepsis management protocol or a legal determination of any particular AI product's regulatory classification.

The article does not provide patient-specific medical advice, authorize automated antimicrobial treatment or source-control decisions, or replace professional clinical judgment.

Sepsis assessment, diagnosis, antimicrobial treatment, hemodynamic resuscitation, source-control decisions and emergency management must remain under the responsibility of appropriately qualified healthcare professionals, consistent with applicable Vietnamese requirements, current clinical guidance and locally approved procedures.

AI-generated predictions must not delay urgent clinical assessment or treatment. A positive AI alert should not automatically trigger antimicrobial treatment or an invasive procedure without appropriate clinical consideration.

The evidence discussed does not establish that AI-assisted sepsis recognition necessarily reduces mortality, organ dysfunction or other adverse outcomes in Vietnamese healthcare settings. Local validation, supervised implementation, meaningful professional oversight and ongoing evaluation remain necessary before claims of clinical effectiveness can be made.

The international guidance discussed primarily concerns adults with sepsis or septic shock. Pediatric, maternal and other specialized populations may require separate clinical recommendations.

Digital Medicine Vietnam (DMVN) | Evidence and regulatory review: November 1, 2026.